An Observational Phase IV Non Interventional Study Evaluating Further the Safety of Rituximab in Combination With Various Chemotherapies for the Treatment of Patients With CD20- Positive B-cell Chronic Lymphocytic Leukaemia in Greece
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Lymphocytic Leukemia, Chronic
Both
Lymphocytic Leukemia, Chronic
Trial Information
An Observational Phase IV Non Interventional Study Evaluating Further the Safety of Rituximab in Combination With Various Chemotherapies for the Treatment of Patients With CD20- Positive B-cell Chronic Lymphocytic Leukaemia in Greece
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Patients with CD20-positive B-cell chronic lymphocytic leukaemia eligible for 1st
line or 2nd line therapy according to the approved summary of product characteristics
(SPC)
Exclusion Criteria:
- Contraindications to MabThera/Rituxan therapy according to the approved SPC
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety: Incidence of adverse events
Outcome Time Frame:
2.5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Greece: Ministry of Health and Welfare
Study ID:
ML22235
NCT ID:
NCT01609023
Start Date:
April 2012
Completion Date:
October 2015
Related Keywords:
- Lymphocytic Leukemia, Chronic
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Chronic Disease
Name | Location |
|---|
